In addition, the data do not address the question of whether TAMs are the major stromal source of CCL20 in RCC patients, which could be examined by isolating cancer cells, macrophages, infiltrating leukocytes and cancer associated fibroblasts from patients followed by measurement of CCL20 secretion in the cultures. The gene discussed is CCL20; the disease is renal cell carcinoma.